SCHEMBL2186240

SCHEMBL2186240

CCOC(=O)c1sc(-c2cc(C#N)c3ccc(OCc4ccccc4)cc3c2)nc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
HSP90AA1 P07900 1/20 0.48
KMT2A Q03164 1/20 0.48
CDC7 O00311 4/20 0.48
DBF4 Q9UBU7 4/20 0.48
LMNA P02545 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
XDH P47989 6/20 0.45
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ABCC4 O15439 1/20 0.43
ABCB11 O95342 1/20 0.43
PGR P06401 1/20 0.43
CHRM1 P11229 1/20 0.43
PDE4A P27815 1/20 0.43
BLVRB P30043 1/20 0.43
TARBP2 Q15633 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12316955 0.88 KMT2A (0.52) MEN1HSP90AA1KMT2ACDC7DBF4
SCHEMBL2185744 0.84 CDC7 (0.53) CDC7DBF4LMNATRPM8XDH
SCHEMBL2186318 0.84 CDC7 (0.55) CDC7DBF4LMNATRPM8XDH
SCHEMBL1329734 0.83 XDH (0.60) CDC7DBF4LMNATRPM8XDH
SCHEMBL20195692 0.82 CDC7 (0.49) CDC7DBF4LMNATRPM8XDH
SCHEMBL2185472 0.78 CDC7 (0.54) CDC7DBF4LMNATRPM8XDH
SCHEMBL12317003 0.77 XDH (0.60) XDHRAB9ASMN1; SMN2ABCC4ABCB11
SCHEMBL1316281 0.74 CDC7 (0.77) CDC7DBF4LMNATRPM8RAB9A
SCHEMBL1981415 0.74 CDC7 (0.54) CDC7DBF4LMNATRPM8XDH
SCHEMBL19523342 0.74 XDH (0.65) CDC7DBF4LMNATRPM8XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2343279-B1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL (JP) 2018-02-28 EP disclosed
US-8263622-B2 Fused-ring derivative and medical application of same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-09-11 US disclosed
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-25 US disclosed
EP-2343279-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207935-A1 FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME XDH, OAT, PON1 MEN1 1851/4885HSP90AA1 4644/4885KMT2A 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.